FDA warned TKTX Numb Store that its lidocaine anesthetic creams are unapproved and misbranded drugs sold without a prescription.
What happened
FDA reviewed the company’s website, www.tktxnumbstore.com, and found three TKTX topical anesthetic creams offered for sale in the United States without a prescription. FDA said the products are intended for use before or during tattooing, piercing, laser treatments, and other cosmetic procedures. FDA said their 5% lidocaine strength, ingredient combinations, and procedure claims do not meet the rules for nonprescription external analgesic drugs, making them unapproved and misbranded.
What FDA found
FDA says the creams are new drugs sold without FDA-approved applications.
FD&C Act §§ 505(a), 301(d), 21 U.S.C. §§ 355(a), 331(d)FDA calls the products misbranded because they are nonprescription drugs that do not meet the legal requirements for marketing under section 505G and have no approved application.
FD&C Act § 502(ee), 21 U.S.C. § 352(ee)FDA says the 5% lidocaine strength is above the 0.5% to 4% range allowed for nonprescription external pain-relief products.
FD&C Act § 505G, 21 U.S.C. § 355h; OTC Monograph M017FDA says the products combine lidocaine with prilocaine and epinephrine, which are not permitted active ingredients under the external analgesic rule, and prilocaine is not permitted in any section 505G order.
FD&C Act § 505G, 21 U.S.C. § 355h; OTC Monograph M017FDA says claims for tattooing, piercing, and laser cosmetic procedures go beyond the allowed uses for external analgesic products and are not included in the external analgesic rule or any other section 505G order.
FD&C Act § 505G, 21 U.S.C. § 355h; OTC Monograph M017FDA says TKTX plus 200% More Volume is also labeled for anorectal disorders but does not meet the anorectal over-the-counter rule, and tattooing and piercing are not included in that rule.
FD&C Act § 505G, 21 U.S.C. § 355h; OTC Monograph M015
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the steps taken to fix the violations, including an explanation of how recurrence will be prevented and copies of related documents. If the company disagrees or cannot finish in that time, it must give its reasoning and supporting information or state the reason for delay and when it will complete the correction.
Who should pay attention
- online sellers of topical anesthetic creams
- tattoo and cosmetic procedure businesses that use or recommend numbing creams
- consumers buying lidocaine creams without a prescription
This is a summary. Read the original letter on fda.gov.